×

The Best Dispensaries in Michigan

The history of marijuana decriminalization in Michigan is combative. As a Rust Belt state, we’re not the most progressive hood around, but we take what we got and make the best of it. Michigan voters first agreed to a medicinal marijuana ballot proposal in 2008. What a great November that was. Seriously.

A glimmer of hope for medical and recreational users alike, it was soon met with resistance; including Michigan’s Supreme Court. After wacky Republicans considered legalizing recreational use without a vote, banking on the premise that liberal voters wouldn’t have as much incentive to hit the polls in November, the measure will ultimately appear on the ballot after all.

Since 2014, Detroit’s number of dispensaries, which are now legally known as “provisioning centers” has dropped from 250 to 60. It can be hard to keep track of which ones are operating or aren’t. Some close temporarily; others permanently. Here’s a list of our favorite places in the city that we can depend on – for now – for our nug necessities.

Also, Check out the Leafly List FAQ for more information on how dispensaries are ranked. The Leafly List is based on 100% objective customer feedback and data collected by Leafly. Businesses CANNOT pay for a spot on the list for a website here.

 

1. The REEF Detroit

6640 E 8 Mile Rd Detroit, MI

REEF strives to offer the best service, products, and prices. With its beautiful location and extensive menu, it’s no surprise to see this store at the top of the Leafly List! REEF’s staff members go out of their way to help you find what you need, and they pride themselves on the knowledge they have to offer and in treating all visitors like family.

2. House of Zen

Far East Side

Female-owned with a super welcoming environment
Located on a silent stretch of Mack Ave, just south of Chandler Park, House of Zen is known for making its guests feel super comfortable. Owned by two sisters, House of Zen prides itself on being a black-owned-and-operated business that specializes in premium strains. There’s no mystery as to what you’re getting here: Each strain is clearly labeled with its myriad health benefits, and the staff is ready to take their time and give you a clear and thoughtful recommendation.

3. Holistic Health Wayne

38110 Michigan Ave Wayne, MI

In June of 2016, Holistic Health was the first licensed medical dispensary to open in Wayne, MI, and they’ve been providing medical patients in Wayne with high-quality cannabis, edibles, and concentrates ever since. The staff at this community-focused dispensary are known for recommending the perfect products, and generous weekly giveaways, promotions, and events ensure that savings are passed on to every patient.

4. Green Genie Inc.

24600 West McNichols, Detroit, MI

This friendly dispensary offers a large selection of award-winning products, including flower, edibles, wax, and more. Patients love the team of compassionate budtenders, who are willing to take the time to walk each visitor through the selection process, eventually zeroing in on the products and strains that are right for them.

5. Healing Tree Wellness Center

15308 E. 8 Mile Rd. Detroit, MI

Healing Tree Wellness Center in Detroit is known for its great selection, especially for flower. The well-kept, spacious facility and educated staff will make sure you don’t leave without something to meet your needs.
What People Are Saying:
“I love this place! Great people and fantastic product. The staff knows your name and has the patience to show off their amazing stuff. The security is all really nice and it is just a great atmosphere.” —Phighs01

6. Green River Meds

West Side

Knowledgeable staff that offers exchanges
Along Grand River Avenue just west of Telegraph Road, you’ll find a massive selection of flower, oils, and edibles. The oils can be pricey, but they do the trick. And if you have an issue, they’ll do exchanges, no questions asked. There’s no doubt the strains here work as promised. Surrounded by a quiet residential area, it’s the perfect spot for a quick pick-up.

7. Mile and Lahser

Where the pros go to work, and to shop
Surrounded by pawn shops and beauty supply stores (ya know, 8 Mile stuff), this is the go-to place for Michigan-made munchies. This is medicine, y’all, and the staff knows its business. With easy access for city residents and suburbanites, the clientele is diverse and everybody’s in a good mood. How could you not be?

8. Far West Holistic Center

21221 W 8 Mile Rd, Detroit, MI

Far West Holistic Center goes above and beyond to make their patients feel valued. Free gifts for first-timers, generous referral bonuses, and plenty of secure onsite parking spots are just a few of the reasons this medical dispensary is quickly becoming a favorite among locals and visitors alike.

9. King Seaweed

3600 East 8 Mile Road, Detroit, MI

This popular Detroit dispensary has much of what you’d expect any dispensary on the Leafly List to have: Friendly, knowledgeable budtenders, impressive deals, and high-quality cannabis. What makes them stand out? An onsite doctor two days a week as well as some amazing sea-themed murals. Where else can you explore cannabis strains while standing on a painting of majestic sea creatures?…

Drug fends off kidney cancer progression

New data from an international, multicenter Phase III clinical trial has observed that the experimental targeted treatment everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other therapys. The study was led by Robert Motzer, MD, an attending doctor at Memorial Sloan-Kettering Cancer Center (MSKCC), who will present the findings on May 31 at the annual meeting of the American Society for Clinical Oncology.

 

This study has given us a new and clearly useful tool for treating renal cell tumors, and everolimus is an important step forward in terms of disease management and quality of life for patients living with this disease, said Dr. Motzer.

Kidney cancer is among the ten most common cancers in both men and women. The American Cancer Society estimates that there will be about 54,390 new cases of kidney cancer diagnosed in the US in 2008, and that about 13,010 people will die from the disease.

Everolimus, a once-daily oral treatment, targets the mTOR protein, which acts as a central regulator of tumor cell division, cell metabolism, and blood vessel growth. It is currently being reviewed for the therapy of several other cancers including lymphoma and neuroendocrine tumors.

More than 400 patients participated in this study, all of whom had disease that had progressed with currently available targeted therapies sunitinib and/or sorafenib. Patients were randomized to receive everolimus or placebo. After six months, 26 percent of patients in the everolimus group had disease that had not progressed, in comparison to only 2 percent of the placebo group. The average difference in progression free survival was four months for everolimus, in comparison to 1.9 months for the placebo group.

In February, 2008, an independent monitoring committee stopped the Phase III trial after interim results were positive and allowed scientists to offer everolimus to the patients receiving placebo.

For almost 20 years, we made no headway in the management of advanced kidney cancer, notes Dr. Motzer. Recently, the identification of several new angiogenesis- targeted agents has provided us with new therapy options and an improved outlook for patients with advanced kidney cancer. Based on the results of this trial, everolimus could become another tool in our armamentarium and, in the future, kidney cancer is likely to be managed as a chronic disease with these types of therapy advances.

Everolimus was well tolerated by patients and the most common side effects were mouth ulcers, anemia, skin rash and weakness.…

Cancer risk higher for women in discontinued hormone treatment trial

A follow up study of participants in the Womens Health Initiative (WHI) clinical trial led by a University of North Carolina at Chapel Hill researcher has observed that women who were taking the combined hormone treatment of estrogen plus progestin may have an increased risk of cancer since the intervention was stopped, in comparison to participants in the trials placebo group.

However, the increased risks of heart disease, stroke and blood clots which had been seen in women taking the treatment as part of the WHI trial have diminished in the three years since scientists stopped it, as per a research studyreported in the March 5 issue of the Journal of the American Medical Association.

The studys lead author is Dr. Gerardo Heiss, a Kenan professor of epidemiology in the UNC School of Public Health.

The WHI trial of estrogen plus progestin which included 16,608 healthy postmenopausal women was originally designed to study what effect the hormone therapy would have on cardiovascular disease, cancer risks and bone fractures.

The trial was stopped in July 2002 after participants had been on the treatment for an average of 5.6 years because scientists saw an increased risk of breast cancer and cardiovascular disease in women randomly assigned to hormone treatment, compared with those who received a placebo.

Since then, Heiss and other WHI scientists at collaborating institutions have examined the risks and benefits experienced by 15,730 trial participants who had follow-up visits from July 2002 to March 2005, after they stopped hormone treatment.

Scientists have observed that the yearly event rates for the outcome all cancer was higher for the estrogen plus progestin group (1.56 percent per year [n = 281]) than the placebo group (1.26 percent per year [n = 218]). This reflects a greater risk of invasive breast cancer and other cancers in the estrogen plus progestin group. Eventhough the risk of breast cancer remained elevated during the follow-up, the risk was less than that experienced towards the end of the trial period.

The WHI researchers did not expect to find an increased overall risk of cancer after stopping the estrogen plus progestin, Heiss said. The increased risk is small, but the follow up did indicate there are higher levels of breast cancer, lung cancer, stroke and death among those who had taken this treatment. Thus, there is a need for prevention efforts through healthy lifestyle choices, risk factor control and regular screening activities as recommended by health care practitioners. This is good advice for everyone though, whether they have taken estrogen plus progestin for 3.5 to 8.5 years as in this study or not.

A summary of the risks and benefits (called the global index) included outcomes for coronary heart disease, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture and death due to other causes. The scientists observed that this measure was 12 percent higher in women randomly assigned to receive estrogen plus progestin compared with the placebo, and did not visibly change after the intervention was stopped.

The rates of colorectal cancer did not differ significantly between the two groups and rates of endometrial cancer were lower in the estrogen plus progestin group.

The risk of cardiovascular events was comparable between the two groups in the follow up assessment, Heiss said, meaning that the increased risks seen in women assigned to estrogen plus progestin during the trial period weakened after the study drugs were stopped.

The risk of fractures during the postintervention follow-up was similar among women in both groups for each type of fracture considered: hip, vertebral and other osteoporotic fractures.

The follow-up after stopping estrogen plus progestin use confirms the trials main conclusion that combination hormone treatment should not be used to prevent disease in healthy, postmenopausal women, Heiss said. The most important message to women who have stopped this hormone treatment is the need for continued prevention and screening activities through their physicians, for all important preventable conditions.…

Is treatment for prostate cancer is working?

Scientists at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of therapy for prostate cancer that has spread to the bones. The technique involves measuring diffusion of water within tumors.

“Currently, we have no way of detecting bone tumor response to treatment, even with all of the imaging options we have available. The magnitude of this problem is huge as a number of as 500,000 people in the United States have metastatic breast or prostate cancer to the bone,” says study author Brian D. Ross, Ph.D., professor of radiology and biological chemistry at the U-M Medical School and co-director of the Molecular Imaging Program at the U-M Comprehensive Cancer Center.

Results of the study, which was done in mice, appear in the April 15 issue of Cancer Research.

The imaging technique, called a functional diffusion map, uses a magnetic resonance imaging scan and special software to track the diffusion, or movement, of water through the cells. Scientists mapped the changes in diffusion over the course of therapy. The tumor cells slow the movement of water, so as those cells die, water diffusion increases.

Scientists studied metastatic prostate cancer in mice; half the mice were given chemotherapy to treat the cancer, which was in the bones, while the remaining mice served as an untreated control group. Scientists performed an MRI of bone tumors to collect diffusion data. A functional diffusion map analysis found the mice that did not receive therapy had little or no change in water diffusion, while the treated mice had progressively increasing changes in the functional diffusion map over the three weeks of therapy. Scientists could identify a statistically significant change in diffusion as early as seven days after therapy began.

At the end of the study, the scientists removed the tumors and found the functional diffusion map predicted the tumors response to therapy. Tumors or portions of a tumor that had appeared not to change on the functional diffusion map had not responded to therapy. At the same time, the map accurately predicted which cells were responsive to the chemotherapy.

“The functional diffusion map could serve as an early biomarker indicating that a tumor is responding to therapy. This could allow patients to switch to an alternative treatment without wasting time on a therapy that is not working,” says study author Kenneth Pienta, M.D., professor of internal medicine and urology and director of the Urologic Oncology Program at the U-M Comprehensive Cancer Center.

The American Cancer Society estimates 218,890 men will be diagnosed with prostate cancer this year and 27,050 will die from the disease.

Ross and colleagues have previously studied the functional diffusion map in people with brain tumors and have found the test can identify after only three weeks of therapy more than two months earlier than traditional tests — which patients are responding to chemotherapy or radiation.…

Marker For Aggressive Form Of Breast Cancer

Scientists have linked a structural protein called nestin to a especially deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better therapy.

In the January 15 issue of Cancer Research, scientists from Dartmouth Medical School demonstrate that nestin could represent a selective biological marker for basal epithelial breast tumors, a highly aggressive cancer with similarities to mammary stem cells, the regenerative cells thought to bethe site of breast cancer initiation.

“Patients with this type of breast cancer are at high risk for recurrence,” said James DiRenzo, Ph.D., assistant professor at Dartmouth Medical School. “Ideally, a marker like nestin would enable clinicians to monitor these patients through frequent tests of a biomarker and, in doing so, detect the cancer before it has a chance to come back”.

Basal epithelial tumors lack important molecular targets such as the estrogen receptor, progesterone receptor and Her2. This not only makes positive diagnosis difficult, say researchers, but also eliminates several important lines of treatment, such as tamoxifen or Herceptin, that work well for other breast cancer subtypes.

“Currently, there is no direct means of determining if a breast cancer is a basal epithelial tumor – doctors only know for certain once the other forms of breast cancer are ruled out,” DiRenzo said. “This type of breast cancer is generally difficult to manage, but several important studies have shown that it is more likely than other breast cancer subtypes to respond to certain types of treatment, which highlights the need for a definitive diagnostic marker”.

The basal epithelial breast cancer subtype represents 17 to 37 percent of all breast cancers and is more common in premenopausal African American women than in other demographic groups. Among breast cancers, this subtype is known to have an early age of onset and a very short time between therapy and relapse. It is more usually detected during normal screening mammogram intervals than other screening subtypes, which likely reflects its aggressive nature. These important clinical correlations likely explain why this subtype disproportionately accounts for breast cancer mortality, as per DiRenzo.

In a retrospective study of breast cancer tumors lacking estrogen receptors, progesterone receptors and Her2, DiRenzo and colleagues found extremely high amounts of nestin in 14 of 16 tumor samples examined. While the scientists plan to strengthen their findings with a larger prospective study, their results offer a crucial first step in diagnosis and management of a disease that is notoriously difficult to control. Consistent with other studies showing that breast cancers linked to inherited mutations in BRCA1 display the basal phenotype, DiRenzo and his colleagues found high levels of nestin in these tumors as well.

Nestin is a long filamentous protein found in adult stem cells in the central nervous system. While researchers do not know its exact function, the protein is thought to have a role in stabilizing the structure of adult stem cells as they regenerate and divide into daughter cells.

“Normal basal epithelial tissue produces nestin, but basal epithelial tumors produce a tremendous amount of nestin, which likely represents an abnormal expansion of the basal epithelia.” DiRenzo said. “If it is indeed specific to regenerative cells, then it will make for an excellent diagnostic tool for a cancer of regenerative mammary cells”.

As per the DiRenzo, another important next step will be finding an efficient means of detecting nestin in a clinical screening setting. While it seems unlikely that a blood test would be sufficient, DiRenzo believes that a non-invasive test that collects samples from mammary ducts may enable the development of a screening tool for at-risk patients.…

Skin Rash Actually Signifies Better Outcomes

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly linked to longer survival, as per scientists from the drug’s developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been linked to a survival advantage with EGFR inhibitors – a class of drugs which includes erlotinib, cetuximab, panitumumab and others designed to block overproduction of the epidermal growth factor receptor – but it is the most detailed analysis to date.

The study, reported in the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, reports that for patients taking Tarceva who developed a moderate to severe rash, survival without progression of disease was 245 percent longer than in patients who had a mild rash or none at all. In fact, in the majority of cases, the more severe the rash, the longer a patient’s cancer was held in check, scientists found.

This rash, which often looks like acne, can be unpleasant enough for some people to consider discontinuing therapy, but “it is important for physicians and patients to understand that this a positive event because it means there is likely to be a better clinical outcome,” said the lead author, Bret Wacker, MS Director of Biostatistics at OSI Pharmaceuticals, Inc. “Further studies are needed to both identify patients most likely to develop rash and to determine if dose escalation to induce rash can improve efficacy.”

Eventhough few patients dropped out of the large Phase III clinical trials testing Tarceva in advanced non-small cell lung cancer and pancreas cancer due to the rash, Wacker said he fears those who are taking Tarceva outside of a clinical trial may be likely to stop therapy.

“Some patients are stopping therapy because of the rash, yet those are the ones who are most likely to benefit,” Wacker said. “This is a critical problem and rather than permanently discontinue therapy, patients should talk to their doctor about an effective and proactive strategy to manage the rash while continuing Tarceva treatment.”

As per the researchers, these rashes can be controlled with mild steroids or antibiotics, and in most cases, they will improve with therapy. They are thought to bedue to an inflammatory response as a result of EGFR inhibition in skin tissue, Wacker said.

The analysis looked at two placebo-controlled, double-blind, randomized, Phase III clinical trials testing Tarceva in advanced non-small cell lung cancer and pancreas cancer – studies which led to approval of the agent for treating both cancers. Wacker and his team excluded patients who died in the first month after starting the study because they may not have had time to develop the rash or the rash may have been under-published in these ill patients.

Of the 673 patients in the lung cancer study, called BR.21, and in the Tarceva-treated group, 81 percent developed a rash, the majority of which was grade 2 (The study graded rashes from 1, relatively mild, to 4, severe). The scientists observed that the presence of any rash correlated with overall and progression-free survival and that these correlations increased with the grade of rash. Specifically, Tarceva-treated patients who did not develop a rash survived a median of 3.3 months, in comparison to 7.1 months for those with a grade 1 rash, and 11.1 months for patients with more severe, grade 2 rashes.

They also found, however, that 18 percent of patients treated with a placebo also developed a rash, and that overall survival in these patients was also significantly longer (a median of 8.2 months in comparison to 4.7 months), in comparison to placebo patients who didn’t develop a rash. “We don’t know why some patients treated with a placebo developed a rash, but it could be due to the strength of their immune system, and that is why they survived longer,” Wacker said.

In the second clinical trial (known as PA.3) that tested Tarceva and the chemotherapy drug gemcitabine against a placebo drug and gemcitabine in 521 patients with advanced pancreas cancer, 71 percent of patients using Tarceva/gemcitabine developed a rash, compared with 30 percent of patients in the placebo group.

This increased rate of rashes in the placebo group makes some sense, Wacker said, because rashes are known to occur with use of gemcitabine chemotherapy. But, unlike the BR.21 study, these pancreas cancer patients with rashes in the placebo group did not experience an increase in survival in comparison to placebo group patients without a rash.

In the Tarceva therapy group, only a more severe rash of grade 2 or higher was linked to increased survival. Patients with a grade 2 rash survived a median of 10.8 months, in comparison to treated patients with no rash (5.4 months) or a grade 1 rash (5.7 months). “These different results may be linked to the addition of gemcitabine with Tarceva, or the lower dose of Tarceva in this study, but we just don’t know,” he said.

Wacker points out that lack of a rash doesn’t necessarily mean that patients will not benefit from Tarceva. “A small percentage of patients who didn’t develop a rash still had relatively long survival,” he said. “But, still, overall, patients who don’t develop a rash don’t do as well as those who do.”…